NEW YORK--Synergy Pharmaceuticals, Inc. (OTC BB: SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that Dr. Gary S. Jacob, the Company's President & Chief Executive Officer, will present at the 2010 Global Hunter Securities (GHS) Healthcare Conference to be held on Tuesday, August 17th, 2010 at the Island Hotel in Newport Beach, California. The Company is scheduled to present at 2:30 PM PDT in Cabana Room 4.
About Synergy Pharmaceuticals, Inc.
Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy's proprietary drug plecanatide (formerly called SP-304) is a synthetic analog of the human gastrointestinal hormone uroguanylin, and acts by activating the guanylate cyclase C (GC-C) receptor on epithelial cells of the GI tract. Plecanatide is presently completing a Phase IIa clinical trial of SP-304 in patients to treat chronic constipation. The Company plans to release topline data from this trial in late September 2010, and initiate a Phase IIb 28-day repeated-oral-dose, placebo-controlled trial in chronic constipation patients in late 2010. More information is available at http://www.synergypharma.com.